Matthew Turner

478 total citations
24 papers, 355 citations indexed

About

Matthew Turner is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Matthew Turner has authored 24 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Oncology and 7 papers in Genetics. Recurrent topics in Matthew Turner's work include Erythropoietin and Anemia Treatment (9 papers), Neutropenia and Cancer Infections (7 papers) and Hemoglobinopathies and Related Disorders (7 papers). Matthew Turner is often cited by papers focused on Erythropoietin and Anemia Treatment (9 papers), Neutropenia and Cancer Infections (7 papers) and Hemoglobinopathies and Related Disorders (7 papers). Matthew Turner collaborates with scholars based in United States, France and Germany. Matthew Turner's co-authors include Karen MacDonald, Matti Aapro, Ivo Abraham, Pere Gascón, Heinz Ludwig, Michael Muenzberg, Carsten Bokemeyer, Pierre Soubeyran, Hans Tesch and Tara Albrecht and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Matthew Turner

22 papers receiving 338 citations

Peers

Countries citing papers authored by Matthew Turner

Since Specialization

Citations

This map shows the geographic impact of Matthew Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Turner more than expected).

Fields of papers citing papers by Matthew Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Turner. The network helps show where Matthew Turner may publish in the future.

Co-authorship network of co-authors of Matthew Turner

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Turner. A scholar is included among the top collaborators of Matthew Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Turner. Matthew Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Accelerating biosimilar market access: the case for allowing earlier standing 2025 ·Journal of Law and the Biosciences ·S. Sean Tu, Rachel W. Goode, Matthew Turner, (unknown)	1
2	Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective 2023 ·BioDrugs ·Hillel P. Cohen, Matthew Turner, Dorothy McCabe, Gillian R. Woollett	14
3	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study) 2015 ·International Urology and Nephrology ·Loreto Gesualdo, Christian Combe, Adrian Covic, Frank Dellanna, David Goldsmith, Gérard M. London, Johannes F.E. Mann, Philippe Zaoui, Matthew Turner, (unknown), Karen MacDonald, Ivo Abraham	3
4	Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) 2015 ·Supportive Care in Cancer ·Pere Gascón, Matti Aapro, Heinz Ludwig, Carsten Bokemeyer, Mario Boccadoro, Matthew Turner, Kris Denhaerynck, Karen MacDonald, Ivo Abraham	59
5	Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns 2015 ·Oncology Research and Treatment ·Hans Tesch, Thomas Ulshöfer, Ursula Vehling‐Kaiser, Bertram Ottillinger, (unknown), Matthew Turner	14
6	Biosimilar granulocyte–colony‐stimulating factor for healthy donor stem cell mobilization: need we be afraid? 2014 ·Transfusion ·Halvard Bönig, P. S. A. Becker, (unknown), Matthew Turner	23
7	Economic Evaluation of Epoetin Alfa Hexal (Binocrit) Compared to Darbepoetin Alfa (Aranesp) in the Treatment of Chemotherapy Induced Anemia (CIA) in Germany 2013 ·Value in Health ·Matthew Turner, (unknown), (unknown)	0
8	Clinical experience with Zarzio® in Europe: what have we learned? 2013 ·Supportive Care in Cancer ·Pere Gascón, Hans Tesch, Karl Verpoort, Maria Sofia Rosati, Nello Salesi, Samir Agrawal, Nils Wilking, Helen F. Barker, Michael Muenzberg, Matthew Turner	88
9	Effectiveness Of Biosimilar Epoetin Alfa For The Treatment Of Chemotherapy-Induced Anemia In Patients With Hematological Malignancies 2013 ·Blood ·Samir Agrawal, (unknown), (unknown), Matthew Turner	1
10	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study 2011 ·Internal and Emergency Medicine ·Loreto Gesualdo, Gérard M. London, Matthew Turner, Christopher S. Lee, Karen MacDonald, David Goldsmith, Adrian Covic, Philippe Zaoui, Christian Combe, Johannes F.E. Mann, Frank Dellanna, Michael Muenzberg, Ivo Abraham	10
11	Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments 2011 ·Critical Reviews in Oncology/Hematology ·Pere Gascón, Matti Aapro, Heinz Ludwig, Nadia Rosencher, Mario Boccadoro, Matthew Turner, Karen MacDonald, Michael Muenzberg, Ivo Abraham	14
12	Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim 2010 ·Critical Reviews in Oncology/Hematology ·Pere Gascón, Matti Aapro, Heinz Ludwig, Nadia Rosencher, Matthew Turner, Min‐Kyoung Song, Karen MacDonald, Christopher S. Lee, Michael Muenzberg, Ivo Abraham	21
13	Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study 2009 ·European Journal of Cancer ·Heinz Ludwig, Matti Aapro, Carsten Bokemeyer, Karen MacDonald, Pierre Soubeyran, Matthew Turner, Tara Albrecht, Ivo Abraham	49
14	Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study 2009 ·Annals of Oncology ·Matti Aapro, Heinz Ludwig, Carsten Bokemeyer, Karen MacDonald, Pierre Soubeyran, Matthew Turner, Tara Albrecht, Ivo Abraham	5
15	Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer 2009 ·Supportive Care in Cancer ·(unknown), Matti Aapro, Karen MacDonald, Pierre Soubeyran, Matthew Turner, (unknown), Tara Albrecht, Ivo Abraham	10
16	Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study 2008 ·European Journal of Cancer ·Matti Aapro, (unknown), Karen MacDonald, Pierre Soubeyran, Michael Muenzberg, Matthew Turner, (unknown), Tara Albrecht, Ivo Abraham	14
17	The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines 2007 ·Supportive Care in Cancer ·Matti Aapro, Ivo Abraham, Carsten Bokemeyer, Heinz Ludwig, Karen MacDonald, Pierre Soubeyran, Matthew Turner	11
18	Promoting evidence-based management of anemia in cancer patients: Background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines 2007 ·Critical Reviews in Oncology/Hematology ·Matti Aapro, (unknown), Karen MacDonald, Pierre Soubeyran, Matthew Turner, Michael Muenzberg, Robert Dunlop, (unknown), Ivo Abraham	4
19	Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care 2007 ·Supportive Care in Cancer ·Matti Aapro, Ivo Abraham, Karen MacDonald, Pierre Soubeyran, Jan Foubert, Carsten Bokemeyer, Michael Muenzberg, (unknown), Matthew Turner	5
20	The occurrence of hemoglobin G (Coushatta) in the Louisiana Coushatta people 1996 ·Journal of Investigative Medicine ·(unknown), Curtiss B. Cook, (unknown), W. Douglas Scheer, Matthew Turner, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), P. Bourgeois, (unknown), (unknown), (unknown), Oksana A. Jackson, Martin H. Johnson, S Paulsen	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact